Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 15, Issue -, Pages S167-S169Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2015.02.010
Keywords
AKT; cancer stem cell; Cirmtuzumab; CLL; Wnt receptor
Categories
Funding
- Leukemia Lymphoma Society [SCOR 7005-14]
- National Institutes of Health grant for the CLL Research Consortium [P01-CA081534]
- California Institute of Regenerative Medicine [DR3-06924]
Ask authors/readers for more resources
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL. (C) 2015 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available